Tumor focality in prostate cancer: implications for focal therapy - PubMed (original) (raw)
Review
Tumor focality in prostate cancer: implications for focal therapy
Markos Karavitakis et al. Nat Rev Clin Oncol. 2011 Jan.
Abstract
In recent years, there has been a growing interest in focal treatment for prostate cancer. Although widely used for the treatment of tumors of the breast and kidney, focal treatment for prostate cancer remains a controversial area. Criticism of focal prostate therapy has been based on the fact that prostate cancer is a multifocal disease. Until now, little attention has been paid to distinguishing between men with unifocal and those with multifocal disease because such information has little clinical relevance when treatment is aimed at the whole gland irrespective of the volume or number of cancers in the prostate. In this Review, we summarize existing knowledge and examine the issue of prostate cancer focality in the context of focal treatment.
Similar articles
- Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT. Sartor AO, et al. Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004. Urology. 2008. PMID: 19095124 - Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.
Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Karavitakis M, et al. Ther Adv Urol. 2012 Aug;4(4):155-60. doi: 10.1177/1756287212447092. Ther Adv Urol. 2012. PMID: 22852025 Free PMC article. - Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG. van der Poel H, et al. World J Urol. 2015 Jul;33(7):907-16. doi: 10.1007/s00345-015-1603-7. Epub 2015 Jun 3. World J Urol. 2015. PMID: 26037891 - Focal therapy for prostate cancer: recent advances and future directions.
Wang A, O'Connor LP, Yerram NK, Nandanan N, Ahdoot M, Lebastchi AH, Gurram S, Chalfin H, Pinto PA. Wang A, et al. Clin Adv Hematol Oncol. 2020 Feb;18(2):116-125. Clin Adv Hematol Oncol. 2020. PMID: 32558805 Review. - Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L; International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Eggener SE, et al. J Urol. 2007 Dec;178(6):2260-7. doi: 10.1016/j.juro.2007.08.072. Epub 2007 Oct 15. J Urol. 2007. PMID: 17936815 Review.
Cited by
- Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.
McClelland S, Maxwell PJ, Branco C, Barry ST, Eberlein C, LaBonte MJ. McClelland S, et al. Cancers (Basel). 2024 Aug 8;16(16):2797. doi: 10.3390/cancers16162797. Cancers (Basel). 2024. PMID: 39199570 Free PMC article. Review. - Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
Segalés L, Juanpere N, Gallarín N, Lorenzo M, López D, Perera-Bel J, Rodriguez-Vida A, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S. Segalés L, et al. Virchows Arch. 2024 Aug;485(2):281-290. doi: 10.1007/s00428-023-03699-z. Epub 2023 Nov 28. Virchows Arch. 2024. PMID: 38017230 Free PMC article. - GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES.
Šamija I, Fröbe A. Šamija I, et al. Acta Clin Croat. 2022 Oct;61(Suppl 3):86. doi: 10.20471/acc.2022.61.s3.13. Acta Clin Croat. 2022. PMID: 36938554 Free PMC article. Review. - A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy.
Finnegan RN, Reynolds HM, Ebert MA, Sun Y, Holloway L, Sykes JR, Dowling J, Mitchell C, Williams SG, Murphy DG, Haworth A. Finnegan RN, et al. Phys Imaging Radiat Oncol. 2022 Mar 6;21:136-145. doi: 10.1016/j.phro.2022.02.011. eCollection 2022 Jan. Phys Imaging Radiat Oncol. 2022. PMID: 35284663 Free PMC article. - Prostate zones and cancer: lost in transition?
Ali A, Du Feu A, Oliveira P, Choudhury A, Bristow RG, Baena E. Ali A, et al. Nat Rev Urol. 2022 Feb;19(2):101-115. doi: 10.1038/s41585-021-00524-7. Epub 2021 Oct 19. Nat Rev Urol. 2022. PMID: 34667303 Review.
References
- World J Urol. 2008 Oct;26(5):457-67 - PubMed
- Cancer Res. 1996 Nov 15;56(22):5272-8 - PubMed
- Nat Rev Clin Oncol. 2009 Apr;6(4):197-206 - PubMed
- J Urol. 2007 Dec;178(6):2260-7 - PubMed
- J Urol. 1999 Feb;161(2):494-8; discussion 498-9 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical